Indianapolis-based pharmaceutical behemoth Eli Lilly has filed lawsuits against four compounders claiming that they sold unapproved products that contain tirzepatide, a key ingredient in the company's weight-loss and diabetes drugs, including top-seller Mounjaro.
The lawsuits against Mochi Health, Fella Health and Delilah, and Henry Meds were filed in the U.S. District Court Northern District of...
Diet weight loss company Noom has entered into an agreement with Eli Lilly's LillyDirect pharmacy provider Gifthealth to help improve access to FDA-approved Zepbound (tirzepatide) single-dose vials for Noom's members with an on-label prescription from a doctor.
The integration with the LillyDirect pharmacy provider expands Noom's approach to weight management by allowing an option for members...
Hybrid weight-inclusive primary and metabolic care provider knownwell announced it will be listed as a care provider on pharma giant Eli Lilly's digital healthcare platform LillyDirect.
knownwell touts itself as a hybrid weight-inclusive provider offering primary care and metabolic health services. The Boston-based company has brick-and-mortar locations in Texas, Chicago and Massachusetts.
Lilly...
Pharmaceutical powerhouse Lilly Digital Health and Lilly Centre for Clinical Pharmacology (LCCP), a wholly owned subsidiary of Eli Lilly and Company, announced the creation of a SGD$42 million digital health innovation hub in Singapore.
The aim of the hub is to increase the research and development of AI-powered digital health technologies, and is part of a five-year plan, supported by the...
AI and RNA genetic-medicine company Genetic Leap is teaming up with pharma giant Eli Lilly to develop genetic medicine therapeutics.
According to the two companies, the partnership expands on a pilot program utilizing Genetic Leap's RNA-targeted AI platform, designed to produce oligonucleotide drugs counter to targets chosen by Lilly in crucial therapeutic areas.
Lilly will provide Genetic Leap...
Pharma giant Eli Lilly has inked a series of deals with four diabetes management companies to integrate with its forthcoming Tempo Pen and Tempo Smart Button products.
The companies that signed strategic international agreements with Eli Lilly are Dexcom, Glooko, myDiabby Healthcare and Roche.
Through the agreements, Eli Lilly’s Tempo Pen and connected Tempo Smart Button will integrate with the...
Diabetes management company Welldoc is teaming up with Eli Lilly on a new licensing and collaboration agreement that promises to integrate the former’s software into the pharma company’s insulin products, which are still in the pipeline.
The partners plan on creating a new version of Welldoc’s BlueStar, an app-based diabetes management platform that will be able to integrate insulin dosing data...
One of the biggest digital health success stories of the two decades is in the diabetes space, especially the continuous glucose monitor (or CGM). The first CGM was approved by the FDA in 1999, but in the last decade we've seen CGMs become smaller, longer lasting and more comfortable, and we've seen huge strides in datasharing as CGM-phone connectivity went from novelty to commodity.
Dexcom has...
MobiHealthNews’ parent company HIMSS and Forrester Research announced today a new research partnership that will survey health system leadership on digital health adoption and measure its impact on patient experience and physician burnout. These findings will be presented at March’s HIMSS Global Health Conference & Exhibition in Orlando.
“Uncovering emerging strategies for quantifying...
Sensors from consumer-grade devices like iPhones, Apple Watches, iPads and Beddit sleep monitors capture enough data to spot mild cognitive impairment or Alzheimer’s disease dementia, according to a new feasibility study conducted jointly by Apple, Eli Lilly and Company and Evidation Health researchers that was presented today at a research conference held in Anchorage, Alaska.
“Over the past few...
.jpg?itok=BD5G-Yu_ "Shaking Hands")
